Portal de Periódicos da CAPES

l -Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials

2012; American Psychiatric Association; Volume: 169; Issue: 12 Linguagem: Inglês

10.1176/appi.ajp.2012.11071114

1535-7228

George I. Papakostas, Richard C. Shelton, John Zajecka, Bijan Etemad, Karl Rickels, Alisabet Clain, Lee Baer, Elizabeth D. Dalton, Garret R. Sacco, David Schoenfeld, Michael Pencina, Allison Meisner, Teodoro Bottiglieri, Erik Nelson, David Mischoulon, Jonathan E. Alpert, James G. Barbee, Sidney Zisook, Maurizio Fava,

Bipolar Disorder and Treatment

Patients with major depression who have an insufficient response to selective serotonin reuptake inhibitors (SSRIs) may benefit from the addition of 15 mg/day of l-methylfolate, the only form of folate that crosses the blood-brain barrier. Adding 7.5 mg/day was no more effective than adding placebo, but 15.0 mg/day plus ongoing SSRI treatment produced a 32% response rate, compared to 15% for augmentation with placebo. Side effects in the two groups were comparable in type and frequency.